Karyopharm’s selinexor combination for multiple myeloma unlikely to see second-line use despite likely FDA approval

Karyopharm selinexor
The SVd combination, which was used in the treatment group in the Phase III BOSTON trial, would not be viable for many patients. Credit: Amayzun.